Amira Gouda
☆    

Egypt,
2018-10-30 10:48
(851 d 23:52 ago)

Posting: # 19500
Views: 3,350
 

 BMI [Design Issues]

Hi,
Are subjects with deviations up to 10% in body mass index (for example: 31.5) eligible to be enrolled in bioequivalence studies?

Thanks
Amira


Edit: Category changed; see also this post #1[Helmut]
Ohlbe
★★★

France,
2018-10-30 11:42
(851 d 22:57 ago)

@ Amira Gouda
Posting: # 19501
Views: 2,794
 

 BMI limits

Dear Amira,

» Are subjects with deviations up to 10% in body mass index (for example: 31.5) eligible to be enrolled in bioequivalence studies?

Deviation from what ?

What did you put in your protocol ? Either the BMI is within the limits set in the protocol and the subject is eligible, or the BMI is outside the limits and the subject is not eligible. Full stop. There is no bargaining.

If your question relates to what limits should be put in the protocol: what is written in the guideline applicable to the country where your trial will be submitted ? If the guideline sets an upper limit of 30, then you should put that limit in the protocol. Again, no bargaining.

A high BMI may not be problematic by itself on a PK or BE point of view, but you may have difficulties drawing the blood samples.

Regards
Ohlbe
Amira Gouda
☆    

Egypt,
2018-10-30 23:06
(851 d 11:33 ago)

@ Ohlbe
Posting: # 19502
Views: 2,771
 

 BMI limits

Dear Ohlbe:
I agree with you, we should strictly follow the study protocol, (NB: protocol BMI range : 18.5 -30 ), but if principal investigator approved this deviation (31.5), recorded in protocol deviation log and submitted to IRB/IEC, what do you think?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]
Ohlbe
★★★

France,
2018-10-30 23:48
(851 d 10:51 ago)

@ Amira Gouda
Posting: # 19503
Views: 2,762
 

 BMI limits

Dear Amira,

» if principal investigator approved this deviation (31.5), recorded in protocol deviation log and submitted to IRB/IEC, what do you think?

That it is still a protocol deviation, and non-compliance with ICH GCP sections 4.5.1 and 4.5.2. Unlikely to cause the rejection of the trial, but if there are too many of these, it may trigger questions and possibly an inspection.

Regards
Ohlbe
ElMaestro
★★★

Denmark,
2018-10-31 09:19
(851 d 01:20 ago)

@ Amira Gouda
Posting: # 19505
Views: 2,801
 

 BMI limits

Hi Amira Gouda,

» I agree with you, we should strictly follow the study protocol, (NB: protocol BMI range : 18.5 -30 ), but if principal investigator approved this deviation (31.5), recorded in protocol deviation log and submitted to IRB/IEC, what do you think?

On basis of my modest experience situations like this tend to arise out of bad planning when the CRO is running out of eligible subjects close the projected start of the study. That's the time when they start approving all sorts of deviations on BMI, blood sugar, ALAT/ASAT, HB/hematocrit and more in order to be able to meet the enrollment target and stay on time.
You do not ever want to be confronted with questions going in that direction.

What did the PI submit to the IEC/IRB and when exactly?

Pass or fail!
ElMaestro
Amira Gouda
☆    

Egypt,
2018-10-31 13:59
(850 d 20:40 ago)

@ ElMaestro
Posting: # 19509
Views: 2,727
 

 BMI limits

» What did the PI submit to the IEC/IRB and when exactly?

Hi,

In such cases PI will submit to IEC/IRB before enrollment of the subject to BE study that he have for example one subject with deviation in BMI which is non significant to the trial and needed to complete sample size

Thanks,


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]
Activity
 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 8 (0 registered, 8 guests [including 1 identified bots]).
Forum time: Sunday 10:40 CET (Europe/Vienna)

Facts are the air of scientists.
Without them you can never fly.    Linus Pauling

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5